Buy & Sell Sana Biotechnology Inc (SANA) – Sana Biotechnology Inc Price Today
Aura AI Summary
Key Stats
- $876.62MMarket Cap
- HealthSector
- -29.84%3M Drawdown
- $850.81MEnterprise Value
- -Dividend Yield
- 50% Buy | 50% SellTrading Activity
- 11 daysTypical Hold Time
Sana Biotechnology Inc (SANA) is currently valued at a market capitalization of $876.62M, with an enterprise value of $850.81M. Over the past 52 weeks, Sana Biotechnology Inc has traded between a low of $2.6 and a high of $5.92, highlighting its annual price range. Over the past three months, Sana Biotechnology Inc has recorded a drawdown of -29.84%, reflecting recent price volatility. On average, investors hold Sana Biotechnology Inc for approximately 11 days, indicating typical investor behavior on the platform.
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Most Recent News
Tourism surges at Hengdian World Studios as Pursuit of Jade tops global C-drama charts.
Hengdian World Studios saw a major spike in visitors after the Chinese drama Pursuit of Jade, filmed mostly at the studio, topped international streaming charts and search volumes in 15 countries. During the May holiday, over 80,000 tourists visited ...

Global sputtering equipment market to reach $4.19B by 2035, driven by semiconductor and solar industry growth.
The global sputtering equipment market is projected to grow from USD 2.41 billion in 2025 to USD 4.19 billion by 2035, at a CAGR of 5.83%. Growth is fueled by rising demand for high-performance semiconductors, flat panel displays, and photovoltaic so...

Japan approves Sanofi's Sarclisa subcutaneous formulation for multiple myeloma treatment
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
